MECHANISMS OF IMIQUIMOD INDUCED REGESSION IN LENTIGO MALIGNA - MECHANISM OF IMIQUIMOD INDUCED REGRESSION IN LENTIGO MALIGNA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-001941-14-GB

Enrollment

Registered

2005-09-16

Start date

2006-05-15

Completion date

Unknown

Last updated

2013-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lentigo maligna

Interventions

Trade Name: Aldara Pharmaceutical Form: Cream

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults suffering from lentigo maligna ammenable to surgical excision. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patients with lentigo maligna melanoma Patients taking systemic immunosuppressant drugs eg renal transpalnt patients Patients unable to comply with instructions

Design outcomes

Primary

Measure	Time frame
Main Objective: To study the mechanism of action of imiquimod in this condition.;Secondary Objective: ;Primary end point(s): Surgical excision of lesion as per standard practice.	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026